Trends in Drug Development for Hyperlipidemia

Problem - Risk of a Cardiovascular Event 

While cholesterol control has been dramatically improved, widely used drugs such as statins, Ezetimibe and PCSK9 inhibitors have not substantially decreased the risk of a cardiovascular event.

Significance of TG Control 

A recent study highlights the significance of triglyceride (TG) control. New drug development that inhibits regulating factors of LPL activity that is critical for TG metabolism has been progressing on a fast track.

Future Drug Development (Angptl3, ApoC3, Angptl4 and Angptl8 inhibitors)

The factors that negatively regulate LPL activity like Angptl3 inhibitors and recent hot topics “the development of ApoC3 inhibitors” have been actively discussed by researchers. It is expected that drug development might be focused on Angptl4 inhibitors and/or Angptl8 inhibitors in near future.

Possible Drug Development Target (ApoA5 and GPIHBP1) 

Factors that positively regulate LPL activity like ApoA5 or GPIHBP1 might be targeted for drug development for the purpose of TG controls. It is especially suggested by genome analysis that ApoA5 could be an important risk factor for early-onset myocardial infarction as much as LDL receptors.

Learn more about our Lipid Metabolism Related Products